/BIOSGN.ST
BIOSGN.ST Stock - Biosergen AB
Healthcare|BiotechnologySTO
$42.60-3.18%
$1.40 (-3.18%) • Dec 23
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.23
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $46.86
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BIOSGN.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$42.17 – $43.03
TARGET (TP)$48.99
STOP LOSS$39.19
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.32
52W High$67.80
52W Low$28.10
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $8.57M | $4.43M |
| Gross Profit | N/A | $-456,000 | $-280,000 | $-213,600 | $-6,096,000 |
| Gross Margin | N/A | N/A | N/A | -2.5% | -137.5% |
| Operating Income | $-20,692,000 | $-27,265,000 | $-34,129,000 | $-33,706,000 | $-6,226,000 |
| Net Income | $-19,195,000 | $-27,037,000 | $-34,048,000 | $-34,318,000 | $-6,724,000 |
| Net Margin | N/A | N/A | N/A | -400.3% | -151.7% |
| EPS | $-8.00 | $-60.00 | $-109.00 | $-64.00 | $-26.00 |
Company Overview
Biosergen AB, a biopharmaceutical company, engages in the development of antifungal products. It is developing BSG005, an antifungal drug candidate for the treatment of life threatening invasive fungal diseases. The company was founded in 2004 and is headquartered in Solna, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BIOSGN.STBeat Rate
38%
Last 8 quarters
Avg Surprise
-11.5%
EPS vs Estimate
Beats / Misses
3/3
2 met exactly
Latest EPS
$-5.18
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
+14.3%
$-0.09vs$-0.10
Q2 24
-36.0%
$-0.14vs$-0.10
Q3 24
No data
Q4 24
No data
Q1 25
0.0%
$-0.02vs$-0.02
Q2 25
0.0%
$-0.02vs$-0.02
Q4 25
-159.1%
$-5.18vs$-2.00
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 19, 2025 | $-2.00 | $-5.18 | -159.1% | ✗ MISS |
Q2 2025 | May 21, 2025 | $-0.02 | $-0.02 | 0.0% | = MET |
Q1 2025 | Mar 5, 2025 | $-0.02 | $-0.02 | 0.0% | = MET |
Q4 2024 | Nov 8, 2024 | — | $-0.03 | — | — |
Q3 2024 | Aug 30, 2024 | — | $-0.04 | — | — |
Q2 2024 | May 31, 2024 | $-0.10 | $-0.14 | -36.0% | ✗ MISS |
Q1 2024 | Feb 29, 2024 | $-0.10 | $-0.09 | +14.3% | ✓ BEAT |
Q4 2023 | Nov 30, 2023 | — | $-0.15 | — | — |
Q3 2023 | Aug 14, 2023 | $-0.28 | $-0.19 | +32.1% | ✓ BEAT |
Q2 2023 | May 31, 2023 | $-0.51 | $-0.18 | +64.7% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-0.37 | $-0.40 | -8.1% | ✗ MISS |
Q3 2022 | Sep 30, 2022 | — | $-0.30 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.17 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.11 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.19 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.21 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.31 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.16 | — | — |
Latest News
Loading news...
Frequently Asked Questions about BIOSGN.ST
What is BIOSGN.ST's current stock price?
Biosergen AB (BIOSGN.ST) is currently trading at $42.60 per share. The stock has moved -3.18% today.
What is the analyst price target for BIOSGN.ST?
No analyst price targets are currently available for this stock.
What sector is Biosergen AB in?
Biosergen AB operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is BIOSGN.ST's market cap?
Biosergen AB has a market capitalization of $0.10 billion, making it a small-cap company.
Does BIOSGN.ST pay dividends?
No, Biosergen AB does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACTI.ST
Active Biotech AB (publ)
$0.04
Mkt Cap: $0.1B
ARCOMA.ST
Arcoma AB
$7.50
Mkt Cap: $0.1B
BIOVIC-B.ST
Biovica International AB (publ)
$0.34
Mkt Cap: $0.1B
CMOTEC-B.ST
Scandinavian ChemoTech AB (publ)
$4.79
Mkt Cap: $0.1B
NICA.ST
Nanologica AB (publ)
$0.71
Mkt Cap: $0.1B
NXTCL.ST
NextCell Pharma AB
$0.70
Mkt Cap: $0.1B
PILA.ST
Pila Pharma AB (publ)
$2.20
Mkt Cap: $0.1B
SCIB.ST
SciBase Holding AB (publ)
$0.36
Mkt Cap: $0.1B
SPRINT.ST
Sprint Bioscience AB (publ)
$1.45
Mkt Cap: $0.2B
XBRANE.ST
Xbrane Biopharma AB (publ)
$10.88
Mkt Cap: $0.1B
Explore stocks similar to BIOSGN.ST for comparison